Breakthrough Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplantation
暂无分享,去创建一个
F. Farina | F. Ciceri | P. Vezzulli | F. Barzaghi | E. Orsenigo | F. Giglio | J. Peccatori | R. Greco | C. Corti | C. Oltolini | D. Clerici | M. L. Lupo Stanghellini | C. Liberatore
[1] P. Woo,et al. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. , 2021, The Lancet. Infectious diseases.
[2] E. Poeschla,et al. Mucormycosis in Hematopoietic Cell Transplant Recipients and in Patients With Hematological Malignancies in the Era of New Antifungal Agents , 2020, Open forum infectious diseases.
[3] L. Pagano. Faculty Opinions recommendation of A single center, open-label trial of isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplant (HCT). , 2020 .
[4] Yeon Joo Lee,et al. A single center, open-label trial of isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplant (HCT). , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] An Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus Species or Rare Molds , 2020, Case Medical Research.
[6] M. Christner,et al. Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008-2019. , 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[7] C. Kauffman,et al. Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia , 2020, Mycopathologia.
[8] H. Badali,et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. , 2019, The Lancet. Infectious diseases.
[9] L. Pagano,et al. Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management. , 2019, Medical mycology.
[10] D. Pakstis,et al. Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope® , 2019, Critical reviews in microbiology.
[11] P. Ljungman,et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. , 2018, The Journal of antimicrobial chemotherapy.
[12] D. Kontoyiannis,et al. Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] D. Breilh,et al. Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis , 2018, Oncotarget.
[14] A. Ibrahim,et al. Challenges in the diagnosis and treatment of mucormycosis. , 2018, Medical mycology.
[15] S. Ranque,et al. Scedosporium and Lomentospora: an updated overview of underrated opportunists. , 2018, Medical mycology.
[16] L. Pagano,et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients , 2016, Haematologica.
[17] J. Perfect,et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. , 2016, The Lancet. Infectious diseases.
[18] M. Cuenca‐Estrella,et al. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] P. Chiusolo,et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[20] L. Pagano,et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[21] L. Pagano,et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[22] P. Hamal,et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[23] Thomas J Walsh,et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] L. Pagano,et al. Scedosporiosis in patients with acute leukemia: a retrospective multicenter report , 2008, Haematologica.
[25] B. Thiers. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia , 2008 .
[26] J. Perfect,et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.
[27] J. Lipton,et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.
[28] W. Leisenring,et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] Nina Singh,et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] O. Sezer,et al. Mucormycoses , 2001, Mycoses.
[31] A. Favero,et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. , 2001, Haematologica.